Fusion of Cardiac Computed Tomography Angiography (CTA) and 18F-Fluorodesoxyglucose Positron Emission Tomography (FDG-PET) to Determine Normal Peri-annular FDG Uptake after Aortic Valve Implantation

Fusion of Cardiac Computed Tomography Angiography (CTA) and 18F-Fluorodesoxyglucose Positron Emission Tomography (FDG-PET) to Determine Normal Peri-annular FDG Uptake after Aortic Valve Implantation - PROSPECTA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43910

Enrollment

Registered

2013-04-02

Start date

2013-05-30

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endocarditis prosthetic heart valve

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - age > 50 years - patients after uncomplicated PHV implantation - Normal routine follow-up TTE - 5 weeks or 12 weeks or 12 months after PHV implantation - weight

Exclusion criteria

Exclusion criteria: - Known contrast allergy - Known renal impairment (GFR

Design outcomes

Primary

Measure	Time frame
18F-FDG/PET baseline uptake measured by the QVSH value and the SUV ratio*s around the PHV in early, late and possibly also in the chronic postoperative phase: 5 (± 1) weeks, 12 (± 2) weeks and 12 (± 2) months respectively.	—

Secondary

Measure	Time frame
- Feasibility of hybrid fusion (diagnostic CTA and PET): percentage of patients for which it is possible to fuse FDG-PET images and cardiac CTA images - Artefacts (region, extend and type and location) during assessment with FDG-PET/CTA will be described	—

Countries

Netherlands

Outcome results